These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25412790)

  • 41. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
    Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
    J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
    [No Abstract]   [Full Text] [Related]  

  • 42. Emerging therapies in psoriasis: a systematic review.
    Lee EB; Amin M; Bhutani T; Wu JJ
    Cutis; 2018 Mar; 101(3S):5-9. PubMed ID: 29718027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early videocapillaroscopic changes of the psoriatic skin after anti-tumour necrosis factor alpha treatment.
    De Angelis R; Gasparini S; Bugatti L; Filosa G
    Dermatology; 2005; 210(3):241-3. PubMed ID: 15785057
    [No Abstract]   [Full Text] [Related]  

  • 45. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
    Campa M; Menter A
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1337-1344. PubMed ID: 27687859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical experience with infliximab biosimilar in psoriasis.
    Ricceri F; Pescitelli L; Lazzeri L; Prignano F
    Br J Dermatol; 2017 Dec; 177(6):e347-e348. PubMed ID: 28646577
    [No Abstract]   [Full Text] [Related]  

  • 47. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
    Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
    Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutics: Silencing psoriasis.
    Crow JM
    Nature; 2012 Dec; 492(7429):S58-9. PubMed ID: 23254974
    [No Abstract]   [Full Text] [Related]  

  • 49. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
    Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
    Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of severe psoriasis with anti-TNF-alpha-antibody and methotrexate].
    Dalaker M; Bonesrønning JH
    Tidsskr Nor Laegeforen; 2003 Apr; 123(8):1070-1. PubMed ID: 12760225
    [No Abstract]   [Full Text] [Related]  

  • 51. Combination therapy of biologics with traditional agents in psoriasis.
    Guenther LC
    Skin Therapy Lett; 2011 Jun; 16(6):1-3. PubMed ID: 21833461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice.
    Cohen AD; Wu JJ; Puig L; Chimenti S; Vender R; Rajagopalan M; Romiti R; de la Cruz C; Skov L; Zachariae C; Young HS; Foley P; van der Walt JM; Naldi L; Prens EP; Blauvelt A
    Br J Dermatol; 2017 Dec; 177(6):1495-1502. PubMed ID: 28646580
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of secukinumab in the treatment of psoriasis.
    Blauvelt A
    Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Unmet needs in the treatment of psoriasis.
    Kragballe K; van de Kerkhof PC; Gordon KB
    Eur J Dermatol; 2014; 24(5):523-32. PubMed ID: 25115238
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hair regrowth following TNF-α blockade in coexisting psoriasis vulgaris and alopecia areata.
    Ono S; Miyachi Y; Arakawa A
    Eur J Dermatol; 2013; 23(4):537. PubMed ID: 24047580
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
    Moreno-Ramírez D
    Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
    [No Abstract]   [Full Text] [Related]  

  • 58. A case of generalized psoriasiform and pustular eruption induced by infliximab: evidence for skin-homing Th17 in the pathogenesis.
    Teraki Y; Tanaka S; Hitomi K; Izaki S
    Br J Dermatol; 2010 Dec; 163(6):1347-51. PubMed ID: 20731653
    [No Abstract]   [Full Text] [Related]  

  • 59. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
    Takahashi MD; Castro LG; Romiti R
    Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
    [No Abstract]   [Full Text] [Related]  

  • 60. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts.
    Sánchez-Moya AI; Daudén E
    Br J Dermatol; 2011 Jan; 164(1):208-9. PubMed ID: 21054332
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.